Macular Degeneration Treatment Market: Trends, Growth, and Key Players

The Macular Degeneration Treatment Market is witnessing robust growth, with the global market valued at USD 10.06 billion in 2024 and projected to reach USD 10.77 billion in 2025, climbing to USD 18.59 billion by 2033 at a CAGR of 7.06%. The rising prevalence of retinal disorders and significant investments in research and development are driving this growth, offering new hope to millions affected by age-related vision loss.

📥 Download Sample

Understanding Macular Degeneration
Macular degeneration affects the eye's macula, causing loss of central vision required to see objects clearly. The disease manifests when capillaries near the fovea expand and leak, interfering with light reflection and leading to progressive vision loss. Most vulnerable are individuals aged 50–60. Common symptoms include night blindness, tunnel vision, and central vision loss. Early stages of dry macular degeneration can benefit from nutritional therapy and supplements, while advanced cases require more specialized treatment.

Market Growth Drivers

• Rising impact of retinal disorders: The global increase in retinal diseases, including AMD, is pushing demand for treatments. The WHO recognizes advanced age-related macular degeneration as a leading cause of irreversible blindness.

• Investments in R&D: Ongoing research on dietary, genetic, and environmental factors, along with novel therapies like retinal cell transplants and medications, is expanding treatment options and driving market growth.

Market Restraints

• Limited public awareness of AMD: Despite its prevalence, general knowledge about AMD is low, restricting early detection and treatment adoption.

Market Opportunities

• Rapidly aging population: The UN estimates the 65-and-older population will double by 2050. Aging demographics and innovative healthcare solutions, such as smart contact lenses and gene chips, are expected to further boost market demand.

Regional Insights

• North America: The largest market, projected to grow at a CAGR of 7.10%, driven by an aging population, prevalence of AMD, and strong healthcare infrastructure.

• Europe: Expected to reach USD 3,531.14 million at a CAGR of 6.70%, fueled by R&D investments and public awareness campaigns, particularly in France.

• Asia-Pacific: Japan leads due to its aging population and active R&D collaborations, such as those between Sumitomo Dainippon Pharma and Healios K.K.

• Middle East & Africa: GCC countries are expanding healthcare investments, with AMD prevalence rising among the elderly.

• South America: Brazil shows growth due to increasing elderly population and government-led awareness programs.

Type Insights

• Wet Age-related Macular Degeneration: Highest contributor to the market, growing at a CAGR of 6.98%, responsible for 90% of legal blindness cases.

• Dry Age-related Macular Degeneration: Affects around 80% of AMD patients, often preceding the wet form.

Stage of Disease Insights

• Late-stage AMD: Holds the largest market share, growing at a CAGR of 7.03%, as it involves the most significant vision loss.

• Early and Intermediate AMD: Focused on risk assessment, lifestyle changes, and antioxidant therapy to prevent disease progression.

Route of Administration Insights

• Intravitreal Route: Dominates the market with a CAGR of 7.10%, providing targeted drug delivery for anti-VEGF therapies.

• Intravenous Route: Used for treatments like Visudyne photodynamic therapy to manage wet AMD.

Sales Channel Insights

• Hospitals: Largest segment with a CAGR of 7.04%, offering comprehensive inpatient care.

• Ambulatory Surgical Centers: Increasing demand for outpatient procedures like laser photocoagulation.

Key Players

• Novartis AG

• Pfizer Inc.

• Panoptica

• Bausch Health Companies Inc.

• Regeneron Pharmaceutical Inc.

• Aerie Pharmaceutical Inc.

• REGENXBIO Inc.

• Bayer AG

Recent Developments

• August 2022: Novartis announced plans to spin off the Sandoz division into a standalone business.

• September 2022: Bayer released new cardiorenal results for Kerendia in early-stage chronic kidney disease and type 2 diabetes patients.

Conclusion
The macular degeneration treatment market is poised for significant growth due to the rising prevalence of retinal disorders, increasing R&D investments, and an aging global population. Innovations in treatment methods, targeted therapies, and expanding healthcare infrastructure are set to offer more effective solutions for patients with AMD worldwide.

About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.

Contact Us:
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/